HON
65
-2
ED
48
3
EFX
32
2
OXY
40
3
TGT
25
-24
CAG
30
4
IBM
54
4
EQT
59
2
PBI
60
-5
PDCO
35
-3
QCOM
48
-7
PNW
66
3
HAS
30
2
WAT
47
5
CF
59
3
NTAP
64
2
JNPR
46
3
DHR
35
3
K
53
2
LH
42
2
HON
65
-2
ED
48
3
EFX
32
2
OXY
40
3
TGT
25
-24
CAG
30
4
IBM
54
4
EQT
59
2
PBI
60
-5
PDCO
35
-3
QCOM
48
-7
PNW
66
3
HAS
30
2
WAT
47
5
CF
59
3
NTAP
64
2
JNPR
46
3
DHR
35
3
K
53
2
LH
42
2
Financhill
Back

Plus Therapeutics 10K Form

Sell
35

PSTV
Plus Therapeutics

Last Price:
1.19
Seasonality Move:
7.07%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PSTV News And Ratings

See the #1 stock for the next 7 days that we like better than PSTV

PSTV Financial Statistics

Sales & Book Value

Annual Sales: $224K
Cash Flow: $-3.69M
Price / Cash Flow: 0
Annual Sales: $-0.88
Price / Book: 0

Profitability

EPS (TTM): -2.53000
Net Income (TTM): $-12.89M
Gross Margin: $5.51M
Return on Equity: 0%
Return on Assets: 0%

Plus Therapeutics Earnings Forecast

Key Plus Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 21 years for PSTV is 184.71%.
  • The Selling, General & Administrative Expenses for PSTV have been equal to 4,570.54% of Gross Profit Margin.
  • The Interest Expense is -2.97% of Operating Income.
  • Per Share Earnings over the last 26 years have been positive in 19 years.

Plus Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: PSTV
CUSIP: 72941H
Website: plustherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PSTV Technical Analysis vs Fundamental Analysis

Sell
35
Plus Therapeutics (PSTV) is a Sell

Is Plus Therapeutics a Buy or a Sell?

  • Plus Therapeutics stock is rated a Sell
    The current Plus Therapeutics [PSTV] share price is $1.19. The Score for PSTV is 35, which is 30% below its historic median score of 50, and infers higher risk than normal.